Evogene Ltd.
EVGN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $8,511 | $5,640 | $1,675 | $930 |
| % Growth | 50.9% | 236.7% | 80.1% | – |
| Cost of Goods Sold | $5,123 | $4,241 | $3,449 | $3,001 |
| Gross Profit | $3,388 | $1,399 | -$1,774 | -$2,071 |
| % Margin | 39.8% | 24.8% | -105.9% | -222.7% |
| R&D Expenses | $14,256 | $18,111 | $17,526 | $19,428 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $10,866 | $9,679 | $10,415 | $9,991 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $25,122 | $27,790 | $27,941 | $29,419 |
| Operating Income | -$21,734 | -$26,391 | -$29,715 | -$31,490 |
| % Margin | -255.4% | -467.9% | -1,774% | -3,386% |
| Other Income/Exp. Net | $3,689 | $404 | -$39 | $1,058 |
| Pre-Tax Income | -$18,045 | -$25,987 | -$29,754 | -$30,432 |
| Tax Expense | $9 | -$33 | $90 | $13 |
| Net Income | -$16,485 | -$23,879 | -$26,638 | -$27,793 |
| % Margin | -193.7% | -423.4% | -1,590.3% | -2,988.5% |
| EPS | -2.89 | -5.23 | -6.46 | -0.68 |
| % Growth | 44.7% | 19% | -850% | – |
| EPS Diluted | -2.89 | -5.23 | -6.46 | -0.68 |
| Weighted Avg Shares Out | 5,697 | 4,569 | 4,121 | 41,014 |
| Weighted Avg Shares Out Dil | 5,697 | 4,569 | 4,121 | 41,014 |
| Supplemental Information | – | – | – | – |
| Interest Income | $957 | $1,248 | $182 | $291 |
| Interest Expense | $124 | $171 | $241 | $403 |
| Depreciation & Amortization | $2,504 | $2,612 | $2,580 | $2,234 |
| EBITDA | -$15,378 | -$23,204 | -$26,933 | -$27,795 |
| % Margin | -180.7% | -411.4% | -1,607.9% | -2,988.7% |